Sells AVISE blood tests that help rheumatologists, primary care physicians and other specialists diagnose and monitor autoimmune and rheumatic diseases.
10-K for FY2025, filed Mar 10, 2026
Clinicians order tests, while insurers, government programs, hospitals and other laboratories, and patients pay. Exagen bills for each test, with collections generally coming 30 to 90 days after billing.
10-K for FY2025, filed Mar 10, 2026Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume…View ↗
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers…View ↗
Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along…View ↗
$66.6M
10-K for FY2025, filed Mar 10, 2026
$66.6M ↗
Exagen markets tests to rheumatologists and physician assistants through its specialized sales force; these clinicians order tests for patients. Insurers, government programs, hospitals and other laboratories, and patients pay for them.
10-K for FY2025, filed Mar 10, 2026
No. It lost $20M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$6.3MView ↗
8-K, filed Nov 10, 2026
The company reiterated full-year 2026 revenue guidance of $72 million to $75 million.View ↗
Growing. Revenue grew 38% in 4 years, from $48.3M in FY2021 to $66.6M in FY2025, about 8% a year.
Expanded AVISE CTD panel
The earlier report described AVISE CTD as a broad test for connective-tissue diseases; the latest says its panel added biomarkers used to diagnose lupus and rheumatoid arthritis.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 10, 2026We market testing products under our AVISE® brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune…View ↗
Since launching AVISE® CTD, we have produced an extensive body of peer-reviewed literature supporting the test’s clinical validity and…View ↗
Competes with ARUP Laboratories, Laboratory Corporation of America Holdings, Mayo Clinic, Quest Diagnostics, Aqtual, AMPEL BioSolutions, DxTerity Diagnostics, Genalyte, Immunovia, Oncimmune Holdings, and Progentec Diagnostics
10-K for FY2025, filed Mar 10, 2026The traditional methods used by healthcare providers to test patients with CTD-like symptoms are the main competitors of our AVISE® testing…View ↗
Loading...